Page last updated: 2024-10-19

melatonin and Chronic Disease

melatonin has been researched along with Chronic Disease in 96 studies

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"To evaluate the effect of short- and long-term administration of melatonin on central brain-derived neurotrophic factor (BDNF) levels in rats with acute and chronic inflammatory pain."9.20Short- but not long-term melatonin administration reduces central levels of brain-derived neurotrophic factor in rats with inflammatory pain. ( Caumo, W; Laste, G; Lucena da Silva Torres, I; Ripoll Rozisky, J, 2015)
"Melatonin treatment in persons with ID and chronic insomnia decreases daytime challenging behaviour, probably by improving sleep maintenance or by improving circadian melatonin rhythmicity."9.14Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia. ( Braam, W; Curfs, LM; Didden, R; Korzilius, H; Maas, AP; Smits, MG, 2010)
"The effects of exogenous, supraphysiologic doses of melatonin on the total sleep time and daytime alertness of patients with chronic insomnia was examined in a double blind, single crossover study."9.07The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. ( Brown, GM; Cleghorn, JM; MacFarlane, JG; Streiner, DL, 1991)
" Since there is a direct relationship between chronic inflammation and many emerging disorders like cancer, oral diseases, kidney diseases, fibromyalgia, gastrointestinal chronic diseases or rheumatics diseases, the aim of this review is to describe the use and role of melatonin, a hormone secreted by the pineal gland, that works directly and indirectly as a free radical scavenger, like a potent antioxidant."8.91Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. ( Calpena, AC; Clares, B; Sánchez, A, 2015)
"This study investigated the effects of melatonin treatment on adrenal catecholamine content, synthesis, uptake, and vesicular transport induced by the chronic unpredictable mild stress (CUMS) model of depression in rats."7.91Melatonin treatment affects changes in adrenal gene expression of catecholamine biosynthesizing enzymes and norepinephrine transporter in the rat model of chronic-stress-induced depression. ( Dronjak, S; Jovanovic, P; Spasojevic, N; Stefanovic, B, 2019)
"Preclinical studies have shown that melatonin exercised antidepressant-like and anxiolyticlike effects in animal models of anxiety."7.83Anxiety and Hyperlocomotion Induced by Chronic Unpredictable Mild Stress Can Be Moderated with Melatonin Treatment. ( Dronjak, S; Jovanovic, P; Spasojevic, N; Stefanovic, B, 2016)
"Treatment with melatonin reduced/prevented functional and morphological changes induced by chronic ischemia on penile structure and function."7.83Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia. ( Andersson, KE; Mitsui, T; Nomiya, M; Sawada, N; Takeda, M; Zarifpour, M, 2016)
"To study the effect of melatonin, a potent antioxidant both in vitro and in vivo, on hyperoxia-induced oxidant/antioxidant imbalance in the lung of neonatal rats with chronic lung disease (CLD)."7.75[Effect of melatonin on hyperoxia-induced oxidant/antioxidant imbalance in the lung of neonatal rats with chronic lung disease]. ( Fu, JH; Pan, L; Xu, W; Xue, XD, 2009)
"The current study was conducted to investigate the relationship between melatonin and chronic anovulation."7.72Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome. ( Baracat, EC; Prata Lima, MF; Simões, MJ, 2004)
"The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating chronic pain patients from healthy subjects, and patients with idiopathic pain syndromes from patients with neurogenic pain syndromes."7.67Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin. ( Almay, BG; Häggendal, J; Johansson, F; Oreland, L; von Knorring, L; Wetterberg, L, 1986)
"Melatonin treatment improves some aspects of chronic sleep disturbance in individuals with ID."6.73Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. ( Braam, W; Curfs, L; Didden, R; Smits, M, 2008)
"Melatonin has been shown to possess both in vitro and in vivo important antioxidant activities as well as to inhibit the activation of poly (ADP ribose) synthetase."6.41Pharmacological actions of melatonin in acute and chronic inflammation. ( Cuzzocrea, S; Reiter, RJ, 2002)
"Melatonin treatment significantly attenuated the levels of RVSP, thickness of the arteriolar wall, oxidative and inflammatory markers in the hypoxic animals with a marked increase in the eNOS phosphorylation in the lung."5.46Melatonin Attenuates Pulmonary Hypertension in Chronically Hypoxic Rats. ( Fung, ML; Hung, MW; Lau, CF; Poon, AMS; Tipoe, GL; Yeung, HM, 2017)
"Melatonin treatment significantly mitigated the increased expression of NADPH oxidase, pro-inflammatory mediators, and adhesion molecules."5.39Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. ( Fung, ML; Hung, MW; Kravtsov, GM; Lau, CF; Poon, AM; Tipoe, GL, 2013)
"Chagas' disease is a severe health problem in Latin America, causing approximately 50 000 deaths a year, with approximately 18 million infected people."5.37Melatonin in Chagas' disease. Possible therapeutic value. ( Alvarez, CB; Cardinali, DP, 2011)
"Melatonin (MT) is an ubiquitous molecule, representing one of the phylogenetically oldest signaling mechanisms."5.35Tryptophan free diet delays healing of chronic gastric ulcers in rat. ( Brzozowski, T; Burnat, G; Konturek, PC; Konturek, SJ; Zopf, Y, 2008)
"Pre-treatment with melatonin (10(-4) M) showed no significant effect on the vasorelaxation by the nitric oxide donor; sodium nitroprusside (10(-7)-10(-5) M)."5.35Chronic hypoxia inhibits the antihypertensive effect of melatonin on pulmonary artery. ( Ballard, HJ; Balonan, L; Das, R; Ho, S, 2008)
"Melatonin was estimated by RIA in samples taken at 24."5.26Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. ( Arendt, J; Crow, TJ; Ferrier, IN; Johnstone, EC, 1982)
"To evaluate the effect of short- and long-term administration of melatonin on central brain-derived neurotrophic factor (BDNF) levels in rats with acute and chronic inflammatory pain."5.20Short- but not long-term melatonin administration reduces central levels of brain-derived neurotrophic factor in rats with inflammatory pain. ( Caumo, W; Laste, G; Lucena da Silva Torres, I; Ripoll Rozisky, J, 2015)
"Twenty-six patients undergoing ESS for chronic sinusitis and polyp removal were enrolled and randomly assigned to receive either oral clonidine or melatonin as preoperative premedication."5.19Improved quality of surgical field during endoscopic sinus surgery after clonidine premedication--a pilot study. ( Burduk, PK; Cywinski, JB; Kazmierczak, W; Kusza, K; Wawrzyniak, K, 2014)
"Melatonin treatment in persons with ID and chronic insomnia decreases daytime challenging behaviour, probably by improving sleep maintenance or by improving circadian melatonin rhythmicity."5.14Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia. ( Braam, W; Curfs, LM; Didden, R; Korzilius, H; Maas, AP; Smits, MG, 2010)
"To evaluate the long-term safety and subjective sleep effects of ramelteon in adults with chronic insomnia."5.14Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. ( Richardson, GS; Wang-Weigand, S; Zammit, G; Zhang, J, 2009)
"Using a double-blind, placebo-controlled, crossover study, we evaluated the efficacy of 10 mg/d of melatonin for 6 weeks in 22 patients with schizophrenia and TD."5.09Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. ( Barak, Y; Elizur, A; Laudon, M; Shalman, I; Shamir, E; Tarrasch, R; Weizman, R; Zisapel, N, 2001)
"The effects of exogenous, supraphysiologic doses of melatonin on the total sleep time and daytime alertness of patients with chronic insomnia was examined in a double blind, single crossover study."5.07The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. ( Brown, GM; Cleghorn, JM; MacFarlane, JG; Streiner, DL, 1991)
" Since there is a direct relationship between chronic inflammation and many emerging disorders like cancer, oral diseases, kidney diseases, fibromyalgia, gastrointestinal chronic diseases or rheumatics diseases, the aim of this review is to describe the use and role of melatonin, a hormone secreted by the pineal gland, that works directly and indirectly as a free radical scavenger, like a potent antioxidant."4.91Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. ( Calpena, AC; Clares, B; Sánchez, A, 2015)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"This study investigated the effects of melatonin treatment on adrenal catecholamine content, synthesis, uptake, and vesicular transport induced by the chronic unpredictable mild stress (CUMS) model of depression in rats."3.91Melatonin treatment affects changes in adrenal gene expression of catecholamine biosynthesizing enzymes and norepinephrine transporter in the rat model of chronic-stress-induced depression. ( Dronjak, S; Jovanovic, P; Spasojevic, N; Stefanovic, B, 2019)
"Treatment with melatonin reduced/prevented functional and morphological changes induced by chronic ischemia on penile structure and function."3.83Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia. ( Andersson, KE; Mitsui, T; Nomiya, M; Sawada, N; Takeda, M; Zarifpour, M, 2016)
"Preclinical studies have shown that melatonin exercised antidepressant-like and anxiolyticlike effects in animal models of anxiety."3.83Anxiety and Hyperlocomotion Induced by Chronic Unpredictable Mild Stress Can Be Moderated with Melatonin Treatment. ( Dronjak, S; Jovanovic, P; Spasojevic, N; Stefanovic, B, 2016)
" Melatonin has protective effects against cerebral ischemia/reperfusion injury."3.75Melatonin provides neuroprotection by reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfusion in ovariectomized rats. ( Barut, F; Ozacmak, HS; Ozacmak, VH, 2009)
"Previous study has shown that administration of melatonin into the anterior cingulate cortex contralateral to peripheral nerve injury prevented exacerbation of mechanical allodynia with a concurrent improvement of depression-like behavior in Wistar-Kyoto (WKY) rats, a genetic variation of Wistar rats."3.75A combined effect of dextromethorphan and melatonin on neuropathic pain behavior in rats. ( Chou, CW; Hernstadt, H; Lim, G; Ma, Y; Mao, J; Rusanescu, G; Sung, B; Tian, Y; Wang, S; Zhang, L, 2009)
"To study the effect of melatonin, a potent antioxidant both in vitro and in vivo, on hyperoxia-induced oxidant/antioxidant imbalance in the lung of neonatal rats with chronic lung disease (CLD)."3.75[Effect of melatonin on hyperoxia-induced oxidant/antioxidant imbalance in the lung of neonatal rats with chronic lung disease]. ( Fu, JH; Pan, L; Xu, W; Xue, XD, 2009)
" Given that the antioxidant melatonin significantly decreased SCI-induced AQP-1 increases and that hypoxia inducible factor-1alpha was increased in acutely and chronically injured spinal cords, we propose that chronic hypoxia contributes to persistent AQP-1 increases after SCI."3.74Aquaporin 1 - a novel player in spinal cord injury. ( Hulsebosch, CE; Johnson, K; Lee, J; Nesic, O; Perez-Polo, JR; Unabia, GC; Vergara, L; Ye, Z, 2008)
"The current study was conducted to investigate the relationship between melatonin and chronic anovulation."3.72Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome. ( Baracat, EC; Prata Lima, MF; Simões, MJ, 2004)
"Clinicoendoscopic morphological and morphofunctional studies in 50 patients with chronic cholecystitis and 50 patients with chronic biliary pancreatitis have demonstrated that morphometric analysis of the antral stomach endocrine cells secreting melatonin, neurotensin and somatostatin can be used in addition to standard laboratory and device methods for differentiation chronic biliary pancreatitis with biliary pathology."3.71[Morphofunctional characteristics of endocrine gastric cells in chronic biliary pancreatitis]. ( Balashov, VI; Kvetnoĭ, IM; Lipatova, TE; Osadchuk, MA, 2001)
" One measurable variable of the ageing process may be melatonin, known to decrease with age and to be lower in patients with coronary heart disease than in normal individuals."3.69Premature ageing: the link between psychosocial risk factors and disease. ( Nilsson, PM, 1996)
"A haloperidol-treated patient with chronic schizophrenia had a near-arrhythmic circadian rest-activity cycle, whereas rhythms of 6-sulphatoxy-melatonin and core body temperature were of normal amplitude and phase-advanced."3.69A schizophrenic patient with an arrhythmic circadian rest-activity cycle. ( Cajochen, C; Nussbaum, P; Wirz-Justice, A, 1997)
"The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating chronic pain patients from healthy subjects, and patients with idiopathic pain syndromes from patients with neurogenic pain syndromes."3.67Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin. ( Almay, BG; Häggendal, J; Johansson, F; Oreland, L; von Knorring, L; Wetterberg, L, 1986)
"Melatonin treatment improves some aspects of chronic sleep disturbance in individuals with ID."2.73Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. ( Braam, W; Curfs, L; Didden, R; Smits, M, 2008)
" There were no differences in the number or type of adverse events between any active treatment and placebo group."2.72An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. ( Erman, M; Sainati, S; Seiden, D; Zammit, G; Zhang, J, 2006)
"Melatonin was well tolerated by the newborns."2.71Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. ( Amodio, A; Barberi, I; Buonocore, G; Cordaro, V; Cuzzocrea, E; Gitto, E; Reiter, RJ; Romeo, C; Sabatino, G; Trimarchi, G, 2004)
"Melatonin treatment also significantly advanced sleep onset by 57 minutes, sleep offset by 9 minutes, and melatonin onset by 82 minutes, and decreased sleep latency by 17 minutes."2.71Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. ( Coenen, AM; Kerkhof, GA; Meijer, AM; Smits, MG; van der Heijden, K; van Stel, HF, 2003)
"The periodicity of cluster headache suggests involvement of the suprachiasmatic nucleus of the hypothalamus, the biological clock."2.70Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. ( Aubé, M; Dobson, CF; Hamel, E; Magnoux, E; Pringsheim, T, 2002)
"Melatonin has been shown as a specific antioxidant reducing oxidative damage in both lipid and aqueous cell environments."2.47New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. ( García-Mauriño, S; Illanes, M; Motilva, V; Talero, E, 2011)
"Benign cysts of the gland have been related to headache, although the mechanism of production of this assumed clinical manifestation has not been clearly determined, due to the lack of large prospective studies."2.46Some questions provoked by a chronic headache (with mixed migraine and cluster headache features) in a woman with a pineal cyst. Answers from a literature review. ( Jiménez-Martínez, MC; Molina-Martínez, FJ; Vives-Pastor, B, 2010)
"Melatonin is a methoxyindole synthesized and secreted principally by the pineal gland at night under normal environmental conditions."2.43The basic physiology and pathophysiology of melatonin. ( Brun, J; Chazot, G; Claustrat, B, 2005)
"Pain is a multi-dimensional process involving the physical, emotional and perceptual integration of noxious information."2.42Pain in the brain: are hormones to blame? ( Blackburn-Munro, G; Blackburn-Munro, R, 2003)
"Melatonin has been shown to possess both in vitro and in vivo important antioxidant activities as well as to inhibit the activation of poly (ADP ribose) synthetase."2.41Pharmacological actions of melatonin in acute and chronic inflammation. ( Cuzzocrea, S; Reiter, RJ, 2002)
"Melatonin treatment significantly attenuated the levels of RVSP, thickness of the arteriolar wall, oxidative and inflammatory markers in the hypoxic animals with a marked increase in the eNOS phosphorylation in the lung."1.46Melatonin Attenuates Pulmonary Hypertension in Chronically Hypoxic Rats. ( Fung, ML; Hung, MW; Lau, CF; Poon, AMS; Tipoe, GL; Yeung, HM, 2017)
"Melatonin, which promotes the metabolism of many reactive oxygen species (ROS), has antioxidant and neuroprotective properties."1.43Chronic Melatonin Treatment Prevents Memory Impairment Induced by Chronic Sleep Deprivation. ( Alhashimi, FH; Alzoubi, KH; Bani Salama, FM; Khabour, OF; Mayyas, FA; Mhaidat, NM, 2016)
"Melatonin treatment significantly mitigated the increased expression of NADPH oxidase, pro-inflammatory mediators, and adhesion molecules."1.39Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. ( Fung, ML; Hung, MW; Kravtsov, GM; Lau, CF; Poon, AM; Tipoe, GL, 2013)
"Melatonin was dispensed in the highest annual amount of all hypnotic drugs; accounting up to a median of 360 defined daily doses in 9-13 year old boys."1.38Hypnotic drug use among 0-17 year olds during 2004-2011: a nationwide prescription database study. ( Bratlid, T; Furu, K; Handal, M; Hartz, I; Skurtveit, S, 2012)
"The etiology of Chagas' disease, caused by a protozoan parasite Trypanosoma cruzi, has been the focus of considerable discussion, although chronic phase still remains not fully understood."1.37Melatonin and zinc treatment: distinctive modulation of cytokine production in chronic experimental Trypanosoma cruzi infection. ( Abrahão, AA; Brazão, V; Caetano, LC; Del Vecchio Filipin, M; do Prado, JC; Santello, FH; Toldo, MP, 2011)
"Chagas' disease is a severe health problem in Latin America, causing approximately 50 000 deaths a year, with approximately 18 million infected people."1.37Melatonin in Chagas' disease. Possible therapeutic value. ( Alvarez, CB; Cardinali, DP, 2011)
"CCI significantly caused thermal hyperalgesia, cold allodynia and oxidative damage."1.37Effect of nitric oxide in protective effect of melatonin against chronic constriction sciatic nerve injury induced neuropathic pain in rats. ( Gupta, A; Kalonia, H; Kumar, A; Kumar, P; Meena, S, 2011)
"Melatonin (MT) is an ubiquitous molecule, representing one of the phylogenetically oldest signaling mechanisms."1.35Tryptophan free diet delays healing of chronic gastric ulcers in rat. ( Brzozowski, T; Burnat, G; Konturek, PC; Konturek, SJ; Zopf, Y, 2008)
"In melatonin and vitamin C-treated groups, eNOS immunoreactivity was diffuse and the intensity of reaction was (+++) in subepicardial region."1.35Effect of melatonin and vitamin C on expression of endothelial NOS in heart of chronic alcoholic rats. ( Akkuş, D; Narin, F; Ozdamar, S; Sönmez, MF, 2009)
"Pre-treatment with melatonin (10(-4) M) showed no significant effect on the vasorelaxation by the nitric oxide donor; sodium nitroprusside (10(-7)-10(-5) M)."1.35Chronic hypoxia inhibits the antihypertensive effect of melatonin on pulmonary artery. ( Ballard, HJ; Balonan, L; Das, R; Ho, S, 2008)
"Melatonin is a hormone primarily synthesized by the pineal gland and has been shown to govern seasonal and circadian rhythms, as well as the immune system, certain behaviours, and responses to stress."1.35Antidepressant-like effects of melatonin in the mouse chronic mild stress model. ( Caumo, W; Detanico, BC; Elisabetsky, E; Freitas, JJ; Hidalgo, MP; Lhullier, FL; Piato, AL, 2009)
"Melatonin treatment improved all scales except the scale "role due to emotional problems."1.31Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. ( Coenen, AM; Kerkhof, GA; Laurant, MW; Nagtegaal, JE; Smits, MG; van der Meer, YG, 2000)
"Melatonin is a promising treatment alternative for serious sleep problems in blind children."1.31[Melatonin treatment of a blind child with serious sleep disorders]. ( Loge, JH; Ramstad, K, 2002)
" We found that the antioxidant melatonin (500 microg/kg bw) prevents cell death as well as the damage induced by chronic administration of MPTP measured as number of nigral cells, tyrosine hydroxylase levels, and several ultra-structural features."1.31Protective effect of melatonin in a chronic experimental model of Parkinson's disease. ( Antolín, I; del Brío, Mde L; Herrera, F; Martín, V; Mayo, JC; Rodríguez, C; Sainz, RM, 2002)
"Chronic migraine (CM), previously called transformed migraine, is a frequent headache disorder that affects 2%-3% of the general population."1.31Hypothalamic involvement in chronic migraine. ( Abucham, J; Cipolla-Neto, J; Peres, MF; Sanchez del Rio, M; Seabra, ML; Silberstein, SD; Tufik, S; Zukerman, E, 2001)
"Melatonin was estimated by RIA in samples taken at 24."1.26Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. ( Arendt, J; Crow, TJ; Ferrier, IN; Johnstone, EC, 1982)

Research

Studies (96)

TimeframeStudies, this research(%)All Research%
pre-19905 (5.21)18.7374
1990's15 (15.63)18.2507
2000's36 (37.50)29.6817
2010's34 (35.42)24.3611
2020's6 (6.25)2.80

Authors

AuthorsStudies
Zhang, H1
Wei, M1
Sun, N1
Wang, H4
Fan, H1
Can, A1
Tuzer, OC1
Petrova, A1
Kondratiuk, V1
Karpenko, O1
Ostashevska, T1
Krasiuk, E1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J1
Zhang, J3
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J7
Xue, L1
Liu, L2
Yan, X2
Huang, S1
Li, Y6
Xu, T1
Li, C2
Ji, F1
Ming, F1
Zhao, Y2
Cheng, J2
Wang, Y3
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X2
Chen, Y4
Wei, J1
Zhu, C1
Wu, C1
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Liu, C3
Lin, Y1
Dong, Y1
Wu, Y1
Bao, Y1
Yan, H2
Ma, J1
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Li, T1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Yang, Y3
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y1
Shen, P1
Zeng, N1
Wang, L3
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Wang, S2
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J2
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H1
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X1
Cao, Y1
Jia, X1
Xu, S1
Lu, C2
Zhu, H2
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X2
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Li, X4
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Cai, C1
Zhang, Y5
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q1
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Liu, J2
Huang, Y1
Kong, L1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Li, P1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Wang, X1
Qu, G1
Xing, Y1
Xu, X1
Maierhofer, M1
Rieger, V1
Mayr, T1
Liu, Y2
Zhang, Q1
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z1
Liu, H1
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R1
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Zhang, G1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Liu, X1
Sun, M1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z2
Zhou, W2
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y2
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Liu, W2
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L1
Peng, S1
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Feng, Z1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Deng, L1
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B1
Zhao, Z1
Huang, C1
Zhang, X2
Qian, H1
Yang, X1
Sun, Y1
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J1
Yang, E1
Yang, W1
Corbella, S1
Calciolari, E1
Alberti, A1
Donos, N1
Francetti, L1
Marjot, T1
Ray, DW1
Williams, FR1
Tomlinson, JW1
Armstrong, MJ1
Hung, MW3
Yeung, HM2
Lau, CF3
Poon, AMS1
Tipoe, GL2
Fung, ML3
Nabavi, SM1
Nabavi, SF1
Sureda, A1
Xiao, J1
Dehpour, AR1
Shirooie, S1
Silva, AS1
Baldi, A1
Khan, H1
Daglia, M1
Stefanovic, B2
Spasojevic, N2
Jovanovic, P2
Dronjak, S2
Kravtsov, GM1
Poon, AM1
Grigg-Damberger, M1
Ralls, F1
Iwamoto, A1
Kawai, M1
Furuse, M1
Yasuo, S1
Wawrzyniak, K1
Burduk, PK1
Cywinski, JB1
Kusza, K1
Kazmierczak, W1
Brazão, V2
Filipin, Mdel V1
Santello, FH2
Azevedo, AP1
Toldo, MP2
de Morais, FR1
do Prado, JC2
Laste, G1
Ripoll Rozisky, J1
Caumo, W2
Lucena da Silva Torres, I1
Alzoubi, KH1
Mayyas, FA1
Khabour, OF1
Bani Salama, FM1
Alhashimi, FH1
Mhaidat, NM1
Xie, S1
Deng, Y1
Pan, YY1
Wang, ZH1
Ren, J1
Guo, XL1
Yuan, X1
Shang, J1
Liu, HG1
Sánchez, A1
Calpena, AC1
Clares, B1
Zurawek, D1
Kusmider, M1
Faron-Gorecka, A1
Gruca, P1
Pabian, P1
Kolasa, M1
Solich, J1
Szafran-Pilch, K1
Papp, M1
Dziedzicka-Wasylewska, M1
Sawada, N2
Nomiya, M2
Zarifpour, M2
Mitsui, T1
Takeda, M1
Andersson, KE2
Cheng, X1
Zeng, J1
Mendez, N1
Halabi, D1
Spichiger, C1
Salazar, ER1
Vergara, K1
Alonso-Vasquez, P1
Carmona, P1
Sarmiento, JM1
Richter, HG1
Seron-Ferre, M2
Torres-Farfan, C1
Onaolapo, AY1
Adebayo, AN1
Onaolapo, OJ1
Konturek, PC1
Burnat, G1
Brzozowski, T1
Zopf, Y1
Konturek, SJ1
Rogers, NL1
Dinges, DF1
Detanico, BC1
Piato, AL1
Freitas, JJ1
Lhullier, FL1
Hidalgo, MP1
Elisabetsky, E1
Richardson, GS1
Zammit, G2
Wang-Weigand, S1
Hoebert, M1
van der Heijden, KB2
van Geijlswijk, IM1
Smits, MG5
Ozacmak, VH1
Barut, F1
Ozacmak, HS1
Zhang, L1
Lim, G1
Sung, B1
Tian, Y1
Chou, CW1
Hernstadt, H1
Rusanescu, G1
Ma, Y1
Mao, J1
Pan, L1
Xu, W1
Fu, JH1
Xue, XD1
Sönmez, MF1
Narin, F1
Akkuş, D1
Ozdamar, S1
Koch, BC1
van der Putten, K1
Van Someren, EJ2
Wielders, JP1
Ter Wee, PM1
Nagtegaal, JE2
Gaillard, CA1
Braam, W2
Didden, R2
Maas, AP1
Korzilius, H1
Curfs, LM1
Talanov, SA1
Timoshchuk, SV1
Rudyk, OV1
Sahach, VF1
Evans, RW1
Peres, MF2
Molina-Martínez, FJ1
Jiménez-Martínez, MC1
Vives-Pastor, B1
Huillet, A1
Erdie-Lalena, C1
Norvell, D1
Davis, BE1
Motilva, V1
García-Mauriño, S1
Talero, E1
Illanes, M1
Perrig, S1
Espa-Cervena, K1
Pépin, JL1
Kumar, A1
Meena, S1
Kalonia, H1
Gupta, A1
Kumar, P1
Del Vecchio Filipin, M1
Caetano, LC1
Abrahão, AA1
Cardinali, DP2
Alvarez, CB1
Cheshchevik, VT1
Lapshina, EA1
Dremza, IK1
Zabrodskaya, SV1
Reiter, RJ3
Prokopchik, NI1
Zavodnik, IB1
Ganguly, K1
Swarnakar, S1
Hartz, I1
Furu, K1
Bratlid, T1
Handal, M1
Skurtveit, S1
Monti, JM1
BaHammam, AS1
Pandi-Perumal, SR1
Bromundt, V1
Spence, DW1
Brown, GM2
Burmeister, DM1
Campeau, L1
Yamaguchi, O1
Willey, C1
Phillips, B1
Pringsheim, T1
Magnoux, E1
Dobson, CF1
Hamel, E1
Aubé, M1
Blackburn-Munro, G1
Blackburn-Munro, R1
van Stel, HF1
van der Heijden, K1
Meijer, AM1
Coenen, AM2
Kerkhof, GA2
Gitto, E1
Amodio, A1
Romeo, C1
Cuzzocrea, E1
Sabatino, G1
Buonocore, G1
Cordaro, V1
Trimarchi, G1
Barberi, I1
Prata Lima, MF1
Baracat, EC1
Simões, MJ1
Claustrat, B1
Brun, J1
Chazot, G1
Contuk, G1
Ercan, F1
Cetinel, S1
Cikler, E1
Sener, G1
Erman, M1
Seiden, D1
Sainati, S1
Arand, M1
Dagnino-Subiabre, A1
Orellana, JA1
Carmona-Fontaine, C1
Montiel, J1
Díaz-Velíz, G1
Wyneken, U1
Concha, ML1
Aboitiz, F1
Geron, R1
Shurtz-Swirski, R1
Sela, S1
Gurevitch, Y1
Tanasijtchouk, T1
Orr, ZS1
Shkolnik, G1
Tanhilevski, O1
Kristal, B1
Ridderinkhof, KR1
Gunning, WB1
Lack, LC1
Wright, HR1
Das, R1
Balonan, L1
Ballard, HJ1
Ho, S1
Nesic, O1
Lee, J1
Unabia, GC1
Johnson, K1
Ye, Z1
Vergara, L1
Hulsebosch, CE1
Perez-Polo, JR1
Smits, M1
Curfs, L1
Ferrier, IN1
Arendt, J1
Johnstone, EC1
Crow, TJ1
Cagnoni, ML1
Lombardi, A1
Cerinic, MC1
Dedola, GL1
Pignone, A1
Monteleone, P1
Piccolo, A1
Martino, M1
Maj, M1
Sandyk, R3
Iacono, RP1
Jan, JE4
Espezel, H2
Appleton, RE1
Bozhko, GKh1
Tsaritsinskiĭ, VI1
Kulabukhov, VM1
Taranskaia, AD1
Silver, H1
Barash, I1
Odnopozov, N1
Jahjah, N1
Mizruhin, A1
Nilsson, PM1
O'Donnell, ME1
Wirz-Justice, A1
Cajochen, C1
Nussbaum, P1
Rodenbeck, A1
Huether, G1
Rüther, E1
Hajak, G1
Laurant, MW1
van der Meer, YG1
Kopp, C1
Vogel, E1
Rettori, MC1
Delagrange, P1
Misslin, R1
Tai, J1
Hahn, G1
Rothstein, RR1
Osadchuk, MA1
Lipatova, TE1
Kvetnoĭ, IM1
Balashov, VI1
Shamir, E1
Barak, Y1
Shalman, I1
Laudon, M1
Zisapel, N1
Tarrasch, R1
Elizur, A1
Weizman, R1
Sanchez del Rio, M1
Seabra, ML1
Tufik, S1
Abucham, J1
Cipolla-Neto, J1
Silberstein, SD1
Zukerman, E1
Cuzzocrea, S1
Ramstad, K1
Loge, JH1
Antolín, I1
Mayo, JC1
Sainz, RM1
del Brío, Mde L1
Herrera, F1
Martín, V1
Rodríguez, C1
Rachinskiĭ, ID1
MacFarlane, JG1
Cleghorn, JM1
Streiner, DL1
von Knorring, L1
Almay, BG1
Häggendal, J1
Johansson, F1
Oreland, L1
Wetterberg, L1
Cotrozzi, G1
Relli, P1
Amico, A1
Betti, L1
Lupi, R1
Cotzias, GC1
Papavasiliou, PS1
Ginos, J1
Steck, A1
Düby, S1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
SurgerySMART: Studying Melatonin and Recovery in Teens[NCT06093477]40 participants (Anticipated)Interventional2024-07-31Not yet recruiting
Effect of Pre-operative Oral Steroids on Blood Loss in Endoscopic Sinus Surgery for Chronic Rhinosinusitis Without Polyps[NCT05095961]Phase 2/Phase 30 participants (Actual)Interventional2023-03-31Withdrawn (stopped due to Technical difficulties encountered with recording intraoperative blood loss; unable to proceed with study.)
A Phase 3, Open-label, Fixed-dose Study to Determine the Safety of Long-term Administration of TAK-375 in Subjects With Chronic Insomnia[NCT00671086]Phase 31,213 participants (Actual)Interventional2003-02-28Completed
Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504]Phase 425 participants (Actual)Interventional2008-01-31Completed
"Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"[NCT02344316]Phase 231 participants (Actual)Interventional2015-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Abdominal Fat (DEXA).

A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Interventiong (Mean)
Ramelteon3934.86
Placebo (Sugar Pill)5120.92

Change in Insulin Resistance as Measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

InterventionHOMA score (Mean)
Ramelteon2.4
Placebo (Sugar Pill)2.36

Change in Waist Circumference

A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Interventioncm (Mean)
Ramelteon106.09
Placebo (Sugar Pill)108.37

Headache Diary Compliance Rate

Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study. (NCT02344316)
Timeframe: Weeks 12-16 of the study

InterventionParticipants (Count of Participants)
Melatonin11
Placebo10

Medication Adherence as Measured by Number of Openings Per Participant

eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant. (NCT02344316)
Timeframe: "during the At Home Active Study Period or Weeks 5-16"

InterventionMean Number of Openings (Mean)
Melatonin39
Placebo60

Number of Migraine/Migrainous Days Per 28 Day Period

Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary. (NCT02344316)
Timeframe: final 4 weeks of treatment

Interventiondays (Mean)
Melatonin3.6
Placebo4.9

Number of Minutes to Sleep Onset

Number of minutes to sleep onset as measured by a FitBit. (NCT02344316)
Timeframe: 16 weeks

Interventionminutes (Mean)
Melatonin15.2
Placebo17.2

Reviews

18 reviews available for melatonin and Chronic Disease

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Systematic review and meta-analysis on the adjunctive use of host immune modulators in non-surgical periodontal treatment in healthy and systemically compromised patients.
    Scientific reports, 2021, 06-09, Volume: 11, Issue:1

    Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Chronic Disea

2021
Sleep and liver disease: a bidirectional relationship.
    The lancet. Gastroenterology & hepatology, 2021, Volume: 6, Issue:10

    Topics: Body Temperature Regulation; Case-Control Studies; Chronic Disease; Cost of Illness; Disease Progres

2021
Anti-inflammatory effects of Melatonin: A mechanistic review.
    Critical reviews in food science and nutrition, 2019, Volume: 59, Issue:sup1

    Topics: Animals; Anti-Inflammatory Agents; Cardiovascular System; Chronic Disease; Clinical Trials as Topic;

2019
Treatment strategies for complex behavioral insomnia in children with neurodevelopmental disorders.
    Current opinion in pulmonary medicine, 2013, Volume: 19, Issue:6

    Topics: Angelman Syndrome; Central Nervous System Depressants; Child; Child Development Disorders, Pervasive

2013
Evaluating the Oxidative Stress in Inflammation: Role of Melatonin.
    International journal of molecular sciences, 2015, Jul-27, Volume: 16, Issue:8

    Topics: Animals; Chronic Disease; Humans; Inflammation; Melatonin; Neoplasms; Oral Health; Oxidative Stress

2015
Some questions provoked by a chronic headache (with mixed migraine and cluster headache features) in a woman with a pineal cyst. Answers from a literature review.
    Cephalalgia : an international journal of headache, 2010, Volume: 30, Issue:9

    Topics: Chronic Disease; Cluster Headache; Cysts; Female; Humans; Melatonin; Middle Aged; Migraine Disorders

2010
New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin.
    Journal of pineal research, 2011, Volume: 51, Issue:1

    Topics: Animals; Autophagy; Chronic Disease; Colonic Neoplasms; Humans; Inflammatory Bowel Diseases; Melaton

2011
Sleep and circadian rhythm dysregulation in schizophrenia.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Jun-03, Volume: 43

    Topics: Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Humans; Melatonin; Schizophrenia; Schizophr

2013
Is melatonin likely to help children with neurodevelopmental disability and chronic severe sleep problems?
    Archives of disease in childhood, 2002, Volume: 87, Issue:3

    Topics: Child, Preschool; Chronic Disease; Developmental Disabilities; Female; Humans; Learning Disabilities

2002
Pain in the brain: are hormones to blame?
    Trends in endocrinology and metabolism: TEM, 2003, Volume: 14, Issue:1

    Topics: Adrenal Glands; Affect; Animals; Brain; Chronic Disease; Female; Growth Hormone; Hormones; Humans; H

2003
The basic physiology and pathophysiology of melatonin.
    Sleep medicine reviews, 2005, Volume: 9, Issue:1

    Topics: Adaptation, Physiological; Chronic Disease; Circadian Rhythm; Humans; Melatonin; Photoperiod; Sleep;

2005
Treating chronobiological components of chronic insomnia.
    Sleep medicine, 2007, Volume: 8, Issue:6

    Topics: Behavior Therapy; Biological Clocks; Body Temperature; Chronic Disease; Chronotherapy; Circadian Rhy

2007
Use of melatonin in the treatment of paediatric sleep disorders.
    Journal of pineal research, 1996, Volume: 21, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Disabled Persons;

1996
Pharmacological actions of melatonin in acute and chronic inflammation.
    Current topics in medicinal chemistry, 2002, Volume: 2, Issue:2

    Topics: Acute Disease; Animals; Chronic Disease; Humans; Inflammation; Melatonin; Oxidants; Oxidative Stress

2002
Successful treatment of multiple sclerosis with magnetic fields.
    The International journal of neuroscience, 1992, Volume: 66, Issue:3-4

    Topics: Brain; Brain Diseases; Chronic Disease; Demyelinating Diseases; Electromagnetic Fields; Female; Huma

1992
[The most frequent hormonal disorders found in chronic hepatopathy].
    La Clinica terapeutica, 1985, Jan-31, Volume: 112, Issue:2

    Topics: Adrenocorticotropic Hormone; Brain; Calcifediol; Calcium; Chronic Disease; Estradiol; Estrogens; Fem

1985
Metabolic modification of Parkinson's disease and of chronic manganese poisoning.
    Annual review of medicine, 1971, Volume: 22

    Topics: Animals; Brain; Choline; Chronic Disease; Dihydroxyphenylalanine; Drug Synergism; Humans; Manganese

1971

Trials

14 trials available for melatonin and Chronic Disease

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Improved quality of surgical field during endoscopic sinus surgery after clonidine premedication--a pilot study.
    International forum of allergy & rhinology, 2014, Volume: 4, Issue:7

    Topics: Adult; Arterial Pressure; Chronic Disease; Clonidine; Endoscopy; Female; Heart Rate; Hemodynamics; H

2014
Short- but not long-term melatonin administration reduces central levels of brain-derived neurotrophic factor in rats with inflammatory pain.
    Neuroimmunomodulation, 2015, Volume: 22, Issue:6

    Topics: Analysis of Variance; Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Central Nervous Syst

2015
Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:4

    Topics: Adolescent; Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Indenes;

2009
Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia.
    Journal of intellectual disability research : JIDR, 2010, Jan-01, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Circadian Rhythm; Female; Humans; Intel

2010
Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study.
    Headache, 2002, Volume: 42, Issue:8

    Topics: Adjuvants, Immunologic; Adolescent; Aged; Analgesics; Chronic Disease; Circadian Rhythm; Cluster Hea

2002
Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2003, Volume: 42, Issue:11

    Topics: Antioxidants; Child; Chronic Disease; Double-Blind Method; Female; Health Status; Humans; Male; Mela

2003
Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin.
    Journal of pineal research, 2004, Volume: 36, Issue:4

    Topics: Antioxidants; Chronic Disease; Cytokines; Humans; Infant, Newborn; Infant, Premature; Lung Diseases;

2004
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.
    Sleep medicine, 2006, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Chronic Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bli

2006
Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2007, Volume: 46, Issue:2

    Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Chronic Disease; Cir

2007
Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.
    Journal of intellectual disability research : JIDR, 2008, Volume: 52, Issue:Pt 3

    Topics: Adolescent; Adult; Aged; Central Nervous System Depressants; Child; Child, Preschool; Chronic Diseas

2008
The treatment of sleep disorders with melatonin.
    Developmental medicine and child neurology, 1994, Volume: 36, Issue:2

    Topics: Adolescent; Blindness; Child; Child, Preschool; Chronic Disease; Circadian Rhythm; Disabled Persons;

1994
Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
    Archives of general psychiatry, 2001, Volume: 58, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Antipsychotic Agents; Chronic Disease; Corpus Striatum

2001
The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study.
    Biological psychiatry, 1991, Aug-15, Volume: 30, Issue:4

    Topics: Administration, Oral; Adult; Aged; Chronic Disease; Circadian Rhythm; Double-Blind Method; Female; H

1991

Other Studies

65 other studies available for melatonin and Chronic Disease

ArticleYear
Melatonin attenuates chronic stress-induced hippocampal inflammatory response and apoptosis by inhibiting ADAM17/TNF-α axis.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2022, Volume: 169

    Topics: ADAM17 Protein; Animals; Apoptosis; Chronic Disease; Cytokines; Hippocampus; Melatonin; Neuroinflamm

2022
The evaluation of melatonin levels in chronic spontaneous urticaria: A case control study.
    Allergy and asthma proceedings, 2023, 11-15, Volume: 44, Issue:6

    Topics: Adult; Case-Control Studies; Chronic Disease; Chronic Urticaria; Female; Humans; Melatonin; Quality

2023
THE EFFECTIVENESS OF MELATONIN IN THE COMPLEX TREATMENT OF HYPERTENSION IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE.
    Georgian medical news, 2020, Issue:299

    Topics: Antihypertensive Agents; Antioxidants; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Centra

2020
Melatonin Attenuates Pulmonary Hypertension in Chronically Hypoxic Rats.
    International journal of molecular sciences, 2017, May-24, Volume: 18, Issue:6

    Topics: Animals; Antioxidants; Chronic Disease; Hypertension, Pulmonary; Hypoxia; Inflammation; Lung; Melato

2017
Melatonin treatment affects changes in adrenal gene expression of catecholamine biosynthesizing enzymes and norepinephrine transporter in the rat model of chronic-stress-induced depression.
    Canadian journal of physiology and pharmacology, 2019, Volume: 97, Issue:7

    Topics: Adrenal Glands; Animals; Catecholamines; Chronic Disease; Depression; Disease Models, Animal; Gene E

2019
Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia.
    Journal of pineal research, 2013, Volume: 55, Issue:3

    Topics: Animals; Antioxidants; Aorta, Thoracic; Cell Adhesion Molecules; Chronic Disease; Endothelium, Vascu

2013
Effects of chronic jet lag on the central and peripheral circadian clocks in CBA/N mice.
    Chronobiology international, 2014, Volume: 31, Issue:2

    Topics: Animals; Behavior, Animal; Chronic Disease; Circadian Rhythm; Circadian Rhythm Signaling Peptides an

2014
Cardioprotective effects of melatonin against myocardial injuries induced by chronic intermittent hypoxia in rats.
    Journal of pineal research, 2015, Volume: 58, Issue:1

    Topics: Animals; Antioxidants; Biomarkers; Cardiotonic Agents; Chronic Disease; Cytokines; Gene Expression R

2015
Immunomodulatory properties and anti-apoptotic effects of zinc and melatonin in an experimental model of chronic Chagas disease.
    Immunobiology, 2015, Volume: 220, Issue:5

    Topics: Animals; Antigens, CD; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separ

2015
Chronic Melatonin Treatment Prevents Memory Impairment Induced by Chronic Sleep Deprivation.
    Molecular neurobiology, 2016, Volume: 53, Issue:5

    Topics: Animals; Biomarkers; Chronic Disease; Hippocampus; Male; Maze Learning; Melatonin; Memory; Memory Di

2016
Melatonin protects against chronic intermittent hypoxia-induced cardiac hypertrophy by modulating autophagy through the 5' adenosine monophosphate-activated protein kinase pathway.
    Biochemical and biophysical research communications, 2015, Sep-04, Volume: 464, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cardiomegaly; Cardiotonic Agents; Cell Line; Chro

2015
Time-dependent miR-16 serum fluctuations together with reciprocal changes in the expression level of miR-16 in mesocortical circuit contribute to stress resilient phenotype in chronic mild stress - An animal model of depression.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:1

    Topics: Anhedonia; Animals; Biomarkers; Chronic Disease; Corticosterone; Depressive Disorder; Dietary Sucros

2016
Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia.
    The journal of sexual medicine, 2016, Volume: 13, Issue:2

    Topics: Animals; Antioxidants; Atherosclerosis; Cholesterol, Dietary; Chronic Disease; Disease Models, Anima

2016
The anti-aging effects of LW-AFC via correcting immune dysfunctions in senescence accelerated mouse resistant 1 (SAMR1) strain.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Aging; Animals; Antioxidants; Cell Proliferation; Chronic Disease; Cytokines; Drugs, Chinese Herbal;

2016
Gestational Chronodisruption Impairs Circadian Physiology in Rat Male Offspring, Increasing the Risk of Chronic Disease.
    Endocrinology, 2016, Volume: 157, Issue:12

    Topics: Aldosterone; Animals; Blood Pressure; Body Temperature; Chronic Disease; Circadian Rhythm; CLOCK Pro

2016
Exogenous daytime melatonin modulates response of adolescent mice in a repeated unpredictable stress paradigm.
    Naunyn-Schmiedeberg's archives of pharmacology, 2017, Volume: 390, Issue:2

    Topics: Age Factors; Animals; Anti-Anxiety Agents; Antioxidants; Behavior, Animal; Biomarkers; Brain; Chroni

2017
Anxiety and Hyperlocomotion Induced by Chronic Unpredictable Mild Stress Can Be Moderated with Melatonin Treatment.
    Folia biologica, 2016, Volume: 62, Issue:6

    Topics: Animals; Anxiety; Chronic Disease; Dopamine; Gene Expression Regulation, Enzymologic; Grooming; Hipp

2016
Tryptophan free diet delays healing of chronic gastric ulcers in rat.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2008, Volume: 59 Suppl 2

    Topics: Animals; Anti-Ulcer Agents; Blotting, Western; Chronic Disease; Cyclooxygenase 2; Diet; Gastric Muco

2008
Interaction of chronic sleep restriction and circadian system in humans.
    Journal of sleep research, 2008, Volume: 17, Issue:4

    Topics: Adult; Chronic Disease; Female; Humans; Male; Melatonin; Sleep Deprivation; Sleep Disorders, Circadi

2008
Antidepressant-like effects of melatonin in the mouse chronic mild stress model.
    European journal of pharmacology, 2009, Apr-01, Volume: 607, Issue:1-3

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Chronic Disease; Circadian Rhythm; Corticosterone;

2009
Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia.
    Journal of pineal research, 2009, Volume: 47, Issue:1

    Topics: Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Depressants; Chi-Squar

2009
Melatonin provides neuroprotection by reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfusion in ovariectomized rats.
    Journal of pineal research, 2009, Volume: 47, Issue:2

    Topics: Animals; Brain Ischemia; Chronic Disease; Female; Glutathione; Hippocampus; Histocytochemistry; HSP7

2009
A combined effect of dextromethorphan and melatonin on neuropathic pain behavior in rats.
    Brain research, 2009, Sep-08, Volume: 1288

    Topics: Analysis of Variance; Animals; Chronic Disease; Dextromethorphan; Dose-Response Relationship, Drug;

2009
[Effect of melatonin on hyperoxia-induced oxidant/antioxidant imbalance in the lung of neonatal rats with chronic lung disease].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2009, Volume: 11, Issue:7

    Topics: Animals; Animals, Newborn; Antioxidants; Chronic Disease; Female; Hyperoxia; Lung; Lung Diseases; Ma

2009
Effect of melatonin and vitamin C on expression of endothelial NOS in heart of chronic alcoholic rats.
    Toxicology and industrial health, 2009, Volume: 25, Issue:6

    Topics: Alcohol-Induced Disorders; Animals; Antioxidants; Ascorbic Acid; Catalase; Central Nervous System De

2009
Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study).
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:2

    Topics: Aged; Body Temperature; Chronic Disease; Circadian Rhythm; Female; Humans; Hydrocortisone; Kidney; K

2010
[An increased sensitivity of the mitochondrial permeability transition pore to calcium in the heart of rats with chronic deficiency of nigrostriatal dopamine].
    Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994), 2009, Volume: 55, Issue:5

    Topics: Animals; Calcium; Chronic Disease; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hear

2009
Headaches and pineal cysts.
    Headache, 2010, Volume: 50, Issue:4

    Topics: Adult; Central Nervous System Cysts; Chronic Disease; Disease Progression; Gonadal Steroid Hormones;

2010
Complementary and alternative medicine used by children in military pediatric clinics.
    Journal of alternative and complementary medicine (New York, N.Y.), 2011, Volume: 17, Issue:6

    Topics: Adult; Age Factors; Ambulatory Care Facilities; Caregivers; Child; Child Care; Chronic Disease; Comp

2011
[Sleep disorder and pain: the good hypnotic].
    Revue medicale suisse, 2011, Jun-29, Volume: 7, Issue:301

    Topics: Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Anticonvulsants; Behavior Therapy

2011
Effect of nitric oxide in protective effect of melatonin against chronic constriction sciatic nerve injury induced neuropathic pain in rats.
    Indian journal of experimental biology, 2011, Volume: 49, Issue:9

    Topics: Animals; Antioxidants; Arginine; Catalase; Chronic Disease; Disease Models, Animal; Glutathione; Hyp

2011
Melatonin and zinc treatment: distinctive modulation of cytokine production in chronic experimental Trypanosoma cruzi infection.
    Cytokine, 2011, Volume: 56, Issue:3

    Topics: Animals; Antigens, CD; Cell Count; Cell Proliferation; Chagas Disease; Chronic Disease; Concanavalin

2011
Melatonin in Chagas' disease. Possible therapeutic value.
    Medicina, 2011, Volume: 71, Issue:5

    Topics: Animals; Antioxidants; Central Nervous System Depressants; Chagas Cardiomyopathy; Chagas Disease; Ch

2011
Rat liver mitochondrial damage under acute or chronic carbon tetrachloride-induced intoxication: protection by melatonin and cranberry flavonoids.
    Toxicology and applied pharmacology, 2012, Jun-15, Volume: 261, Issue:3

    Topics: Acute Disease; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Bilirubin;

2012
Chronic gastric ulceration causes matrix metalloproteinases-9 and -3 augmentation: alleviation by melatonin.
    Biochimie, 2012, Volume: 94, Issue:12

    Topics: Animals; Antioxidants; Blotting, Western; Chronic Disease; Extracellular Signal-Regulated MAP Kinase

2012
Hypnotic drug use among 0-17 year olds during 2004-2011: a nationwide prescription database study.
    Scandinavian journal of public health, 2012, Volume: 40, Issue:8

    Topics: Adolescent; Child; Child, Preschool; Chronic Disease; Databases, Factual; Drug Prescriptions; Drug U

2012
Effect of melatonin on chronic bladder-ischaemia-associated changes in rat bladder function.
    BJU international, 2013, Volume: 112, Issue:2

    Topics: Animals; Chronic Disease; Ischemia; Male; Melatonin; Rats; Rats, Sprague-Dawley; Urinary Bladder

2013
Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2004, Volume: 37, Issue:7

    Topics: Animals; Anovulation; Chronic Disease; Female; Light; Melatonin; Ovariectomy; Ovary; Pineal Gland; P

2004
Role of melatonin in reducing water avoidance stress-induced degeneration of the liver.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:4

    Topics: Acute Disease; Animals; Avoidance Learning; Chronic Disease; Free Radical Scavengers; Glutathione; L

2005
[Influence of melatonin, serotonin and gastrin on streaming of chronic gastritis at elderly patients].
    Advances in gerontology = Uspekhi gerontologii, 2005, Volume: 16

    Topics: Aged; Apoptosis; Chronic Disease; Disease Progression; Enterochromaffin Cells; Gastric Mucosa; Gastr

2005
[Prescriptions for insomnia].
    MMW Fortschritte der Medizin, 2005, Nov-24, Volume: 147, Issue:47

    Topics: Chronic Disease; Drug Stability; Humans; Hypnotics and Sedatives; Melatonin; Nonprescription Drugs;

2005
Chronic stress decreases the expression of sympathetic markers in the pineal gland and increases plasma melatonin concentration in rats.
    Journal of neurochemistry, 2006, Volume: 97, Issue:5

    Topics: Animals; Biomarkers; Chronic Disease; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; G

2006
Polymorphonuclear leucocyte priming in long intermittent nocturnal haemodialysis patients--is melatonin a player?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:11

    Topics: Chronic Disease; Circadian Rhythm; Female; Humans; Kidney Diseases; Male; Melatonin; Middle Aged; Ne

2006
Chronic hypoxia inhibits the antihypertensive effect of melatonin on pulmonary artery.
    International journal of cardiology, 2008, Jun-06, Volume: 126, Issue:3

    Topics: Animals; Chronic Disease; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; Male; Melatonin;

2008
Aquaporin 1 - a novel player in spinal cord injury.
    Journal of neurochemistry, 2008, Volume: 105, Issue:3

    Topics: Afferent Pathways; Animals; Antioxidants; Aquaporin 1; Astrocytes; Cell Size; Chronic Disease; Disea

2008
Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight.
    Clinical endocrinology, 1982, Volume: 17, Issue:2

    Topics: Adult; Aged; Body Weight; Chronic Disease; Circadian Rhythm; Humans; Male; Melatonin; Middle Aged; S

1982
Melatonin for treatment of chronic refractory sarcoidosis.
    Lancet (London, England), 1995, Nov-04, Volume: 346, Issue:8984

    Topics: Adult; Chronic Disease; Dyspnea; Female; Humans; Lung Diseases; Melatonin; Middle Aged; Sarcoidosis;

1995
Seasonal variation in the dexamethasone suppression test: a longitudinal study in chronic schizophrenics and in healthy subjects.
    Neuropsychobiology, 1994, Volume: 30, Issue:2-3

    Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dexamethasone; F

1994
Rapid normalization of visual evoked potentials by picoTesla range magnetic fields in chronic progressive multiple sclerosis.
    The International journal of neuroscience, 1994, Volume: 77, Issue:3-4

    Topics: Brain; Chronic Disease; Evoked Potentials, Visual; Humans; Magnetic Resonance Imaging; Magnetics; Me

1994
Improvement by picoTesla range magnetic fields of perceptual-motor performance and visual memory in a patient with chronic progressive multiple sclerosis.
    The International journal of neuroscience, 1994, Volume: 78, Issue:1-2

    Topics: Chronic Disease; Electromagnetic Fields; Humans; Male; Melatonin; Memory; Middle Aged; Multiple Scle

1994
Melatonin treatment of chronic sleep disorders.
    Developmental medicine and child neurology, 1995, Volume: 37, Issue:3

    Topics: Administration, Oral; Chronic Disease; Humans; Melatonin; Sleep Wake Disorders; Treatment Outcome; W

1995
[Melatonin excretion in patients with depression under the action of light of increased intensity].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1995, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Bipolar Disorder; Chronic Disease; Depressive Disorder, Major; Female; Fluorometr

1995
Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: evidence for the development of tolerance to selective serotonin re-uptake inhibitor.
    Biological psychiatry, 1996, Jul-01, Volume: 40, Issue:1

    Topics: Adult; Biomarkers; Chronic Disease; Dose-Response Relationship, Drug; Drug Tolerance; Female; Fluvox

1996
Premature ageing: the link between psychosocial risk factors and disease.
    Medical hypotheses, 1996, Volume: 47, Issue:1

    Topics: Aging; Chronic Disease; Coronary Disease; Health Status; Humans; Life Style; Melatonin; Models, Theo

1996
A schizophrenic patient with an arrhythmic circadian rest-activity cycle.
    Psychiatry research, 1997, Nov-14, Volume: 73, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Bed Rest; Body Temperature; Catatonia; Chronic Disease; Circadian Rhyth

1997
Altered circadian melatonin secretion patterns in relation to sleep in patients with chronic sleep-wake rhythm disorders.
    Journal of pineal research, 1998, Volume: 25, Issue:4

    Topics: Adult; Chronic Disease; Circadian Rhythm; Humans; Male; Melatonin; Middle Aged; Radioimmunoassay; Sl

1998
Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome.
    Journal of psychosomatic research, 2000, Volume: 48, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Chronic Disease; Female; Follow-Up

2000
The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice.
    Behavioural pharmacology, 1999, Volume: 10, Issue:1

    Topics: Animals; Antioxidants; Behavior, Animal; Chronic Disease; Exploratory Behavior; Fluoxetine; Male; Me

1999
Melatonin replacement therapy in a child with a pineal tumor.
    Journal of child neurology, 2001, Volume: 16, Issue:2

    Topics: Adolescent; Brain Neoplasms; Child; Chronic Disease; Dose-Response Relationship, Drug; Female; Hormo

2001
[Morphofunctional characteristics of endocrine gastric cells in chronic biliary pancreatitis].
    Klinicheskaia meditsina, 2001, Volume: 79, Issue:9

    Topics: Chronic Disease; Common Bile Duct Diseases; Diagnosis, Differential; Gastric Mucosa; Humans; Melaton

2001
Hypothalamic involvement in chronic migraine.
    Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 71, Issue:6

    Topics: Adult; Anxiety; Case-Control Studies; Chronic Disease; Chronobiology Disorders; Circadian Rhythm; Co

2001
[Melatonin treatment of a blind child with serious sleep disorders].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Apr-20, Volume: 122, Issue:10

    Topics: Blindness; Child, Preschool; Chronic Disease; Developmental Disabilities; Humans; Male; Melatonin; P

2002
Protective effect of melatonin in a chronic experimental model of Parkinson's disease.
    Brain research, 2002, Jul-12, Volume: 943, Issue:2

    Topics: Animals; Axons; Cell Death; Chronic Disease; Disease Models, Animal; DNA Fragmentation; Dose-Respons

2002
[Disordered melatonin metabolism in chronic circulatory insufficiency].
    Kardiologiia, 1978, Volume: 18, Issue:12

    Topics: Aged; Arrhythmias, Cardiac; Cardiovascular Diseases; Chronic Disease; Coronary Disease; Humans; Hype

1978
Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin.
    European archives of psychiatry and neurological sciences, 1986, Volume: 236, Issue:3

    Topics: Adult; Chronic Disease; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydr

1986